A New Benchmark for Taiwan's Biomedical Sacred Mountain: YaoDe Biotech Partners with GuanXin Medical to Bring AI-Driven Pharmaceutical-Grade Standards to Preventive Medicine, Targeting the $430 Billion Global Health Market

As global demographics shift toward super-aging societies and chronic disease prevalence rises annually, the biotech industry has become a strategic battleground for nations. The Taiwanese government recently unveiled its vision of a 'Biomedical Sacred Mountain,' committing $24 billion to its 'National Medicinal Resilience Preparedness Plan.' Riding this wave, YaoDe Biotech and GuanXin Medical have emerged as leaders, officially announcing the extension of pharmaceutical development standards into the health supplement sector using AI big data and 12 years of accumulated drug R&D data. This enables precise, effective preventive medicine solutions to combat the growing challenges of Alzheimer's disease and the 'Five Highs'—hypertension, hyperlipidemia, hyperglycemia, hyperuricemia, and high cholesterol.

Market Outlook: Preventive Medicine Shifts from 'Option' to 'Necessity'

Wang Tian-Di, Chairman of YaoDe Biotech, pointed out that Taiwan has already entered a super-aging society where one in five people is a senior, with shockingly high rates of the 'Five Highs' leading to Taiwan's dialysis rate ranking among the highest globally for years. Wang emphasized that the traditional belief of seeking medical care only when sick can no longer withstand modern societal pressures—'preventive medicine' is now a necessity for modern individuals.

According to market reports, the global health supplement market reached $230.4 billion in 2025 and is projected to surpass $430 billion by 2035. The Asia-Pacific region alone accounts for 38% of global growth. Facing this massive market, YaoDe Biotech and GuanXin Medical’s core advantage lies in moving the safety frontier forward, utilizing AI smart monitoring and big data analytics to help consumers establish precise, preventive health management.

Core Corporate Strength: AI-Driven Drug Development Engine

YaoDe Biotech's most prominent competitive advantage in the biotech field is its powerful AI-assisted R&D capability and technology that shortens development cycles.

Regarding 'AI computing power shortening R&D timelines,' Wang emphasized that traditional protein design and structural simulation can take years, but YaoDe Biotech extensively uses AI simulation technology to identify screening trends and solutions within minutes. This technological edge allows the company to significantly lead in R&D progress. Currently, YaoDe Biotech's drug for Alzheimer's disease has received Taiwan IND Phase II clinical approval and is scheduled to submit a Phase II drug application to the U.S. FDA in June 2026.

In terms of 'precise matching and raw material screening,' YaoDe Biotech leverages a large database built in collaboration with Academia Sinica, Yang Ming Chiao Tung University, and GeneLabs, precisely comparing ingredient compositions from different origins. Using AI simulation, it determines which herbal components are most effective for specific diseases. This 'matching pathway' technical capability greatly reduces R&D costs and increases success rates.

Technical Moat: Pharmaceutical-Grade 'Plant Stem Cell' Process

Unlike general plant extract products on the market, the 'Plant Stem Cell' series jointly launched by YaoDe Biotech and GuanXin Medical demonstrates 12 years of deep R&D, with core technologies including:

1. Seven rigorous processes and precision separation: YaoDe Biotech applies pharmaceutical development standards to the extraction process, precisely controlling temperature, pressure, and concentration. For example, with Ganoderma or Antrodia camphorata, the technical team can precisely isolate specific active ingredients (such as ganoderic acids or triterpenoids), achieving 'taking only what the body needs' and maximizing effectiveness.

2. Synbiotic technology and multi-target design: Employing advanced 'micro-implant encapsulation technology' and the 'synbiotic' concept, YaoDe Biotech does more than provide external nutritional supplementation—it uses AI multi-target technology to identify optimal pathways, creating a favorable internal environment and enhancing the body’s self-repair capabilities.

3. High-spec 'Medicine Replacing Food': YaoDe Biotech insists on applying pharmaceutical R&D safety standards (such as PKPD pharmacokinetic calculations) and data validation to supplements, resolving consumer pain points like 'no noticeable effect' or 'unknown absorption rate.'

Strategic Alliance: Building an Integrated Biomedical Platform

The strategic alliance between YaoDe Biotech Chairman Wang Tian-Di and GuanXin Medical has successfully established a complete industry chain encompassing 'R&D, testing, clinical trials, and sales'—a key reason the company maintains high growth in a saturated market.

This stable 'three-legged' structure (platform, new drugs, distribution) enables YaoDe Biotech to sustain stable, positive growth even in volatile capital markets. The company’s current biotech market value exceeds NT$1.6 trillion, and YaoDe Biotech is actively advancing toward its goal of becoming a trillion-dollar industry.

Capital Strategy and Global Vision: Connecting with NASDAQ

YaoDe Biotech’s strengths extend beyond technology to forward-looking capital strategy. Recently, the company is actively participating in Taiwan government initiatives for listing applications, committed to keeping the best biotech innovations in Taiwan and building an 'Asian NASDAQ.'

Simultaneously, YaoDe Biotech continues to connect with global capital. After enriching its data portfolio, the company plans to pursue a global listing on the U.S. NASDAQ, leveraging worldwide capital to accelerate Alzheimer's drug development and transform Taiwan’s technological edge into a globally impactful 'Taiwan’s Light.'

'The enemy of health has never been disease, but our own mindset,' emphasized Chairman Wang. Amid food safety concerns and price-cutting competition, YaoDe Biotech and GuanXin Medical steadfastly uphold the corporate belief that 'ineffectiveness is the most expensive.' Wang urges consumers not to be misled by price and numbers, but to choose products with laboratory-grade specifications, clear technological origins, and genuine alignment with their needs. True success in health management, he says, is 'comparing yourself to yourself, becoming healthier day by day.'

With the upcoming U.S. FDA Phase II drug application and the launch of Taiwan’s Innovation Board listing, YaoDe Biotech and GuanXin Medical are leading preventive medicine into a new era of AI intelligence and pharmaceutical-grade standards.